St. Jude Children's Research Hospital account plan
Pediatric cancer research and treatment
At a glance
St. Jude is a Memphis non-profit research hospital for sick children, seeing over 9,300 patients a year; FY2025 expenses were $1.9 billion.
St. Jude Children's Research Hospital, Inc. is a not-for-profit research, treatment and education center in Memphis, Tennessee, whose mission is to find the causes of catastrophic childhood illnesses, improve treatments and find cures; no family ever pays the hospital for its child's care. It sees more than 9,300 patients a year, accounting for about 75,000 hospital visits, mostly outpatient within research programs. In the year ended June 30, 2025 total expenses were $1,897,572K, against its own revenues, gains and other support of $341,483K; the gap is funded by its fundraising affiliate ALSAC, which provided net support of $1,878,045K. Total net assets reached $12,561,643K, most of it the hospital's interest in ALSAC's net assets.
Business units
Research
about 47% of FY2025 expenses ($883,216K)Basic science and clinical research in pediatric cancers, blood diseases, gene therapy, viruses and hereditary diseases. Partly funded by research grants and contracts of $162,425K, mostly from government sponsors, plus technology licensing of about $14.7 million.
Patient care services
about 38% of FY2025 expenses ($726,650K)Free treatment of children at the Memphis hospital; net patient service revenue of $141,306K comes only from third-party payors, led by Medicaid. New clinical outpatient facilities with a total estimated cost of $1 billion are expected substantially complete in calendar 2026.
Education, training and community services
about 8% of FY2025 expenses ($146,234K)The fastest-growing expense line, covering the Graduate School of Biomedical Sciences and global outreach, including a $107 million commitment for fiscal 2024 through 2027 to increase global access to childhood cancer medications.
ALSAC (fundraising and awareness affiliate)
A separate not-for-profit that raises funds exclusively for St. Jude; FY2025 revenues, gains and other support were $3,735,743K and net assets $10,765,019K. Led by President and CEO Ike Anand since July 2025.
Subsidiaries
Children's GMP, LLC produces biologics and drugs for research; St. Jude Home Care runs a home health agency in the Memphis area; St. Jude Global Operations Platform enables global activities.
Strategic priorities
- New therapeutic modalities
- Incoming CEO Charles Roberts sees a convergence of technologies, including AI to design small molecules, PROTACs and glues, RNA therapeutics, antibody drug conjugates and CAR-T cells, that can treat childhood cancers more effectively with less toxicity.
- Diseases beyond cancer
- The same modalities could make inherited genetic diseases of children treatable, widening St. Jude's scope to more catastrophic childhood diseases.
- Global expansion
- St. Jude plans to treat more children around the world; ALSAC's six-year $12.9 billion plan aims to provide pediatric cancer cures and treatments globally.
- Clinical outpatient facilities
- A $1 billion outpatient building programme, with $639.5 million in construction in progress at June 30, 2025, is expected substantially complete in calendar 2026.
- Free care for families
- Treatment stays free for patients and families, funded by ALSAC philanthropy.
Investments and deals
- Campus construction
- Capital expenditures rose to $452,643K in FY2025 from $380,188K, and construction in progress grew to $774,406K, mainly for the clinical outpatient facilities.
- IT and cloud
- Computer hardware and software assets grew to $267,965K from $243,416K, with capitalized cloud computing implementation costs.
- Global access to medicines
- Total estimated contributions of $107 million for fiscal 2024 through 2027 under a memorandum with a procurement agency, of which $32 million had been contributed by June 30, 2025.
Challenges and risks
- Federal research funding
- Federal awards expended were $137,833,439 in FY2025, almost all from the Department of Health and Human Services, and incoming CEO Roberts names federal cuts to scientific research funding as a constraint.
- Limited pharma investment
- Pharmaceutical companies invest less in childhood cancers than in adult cancers, which St. Jude cannot fully replace.
- Dependence on ALSAC
- The hospital's own revenues cover a minority of costs, so it depends on ALSAC fundraising and on ALSAC's largely illiquid investment returns.
- Rising costs
- Total expenses rose to $1,897,572K from $1,772,679K, with salaries and benefits at $1,041,996K.
- Reimbursement complexity
- The receivables mix shifted toward Medicaid (41% at June 30, 2025 from 29%), and reimbursement laws are described as extremely complex and subject to interpretation.
What leadership says
“I think we are at the dawn of a new era”
“We can't go all the way and completely replace what pharma does”
“I think this is not rocket science. This is much harder.”
“My role is to make sure that ALSAC is able to deliver on its promises to St. Jude so that St. Jude can continue to dream big”
Where a supplier can help
- Research technology and AI drug design
- Tied to the new therapeutic modalities priority: AI and computational chemistry tools, lab automation and data platforms for small-molecule, RNA and cell therapy research.
- Hospital fit-out and operations
- Tied to the $1 billion clinical outpatient facilities programme: medical equipment, facility systems and moving-in services as the buildings complete in 2026.
- Grant and research administration
- Tied to the federal research funding challenge: grant management and compliance tools that protect and diversify research funding.
- Global programme logistics
- Tied to the global expansion priority: supply chain, procurement and digital health partners for treating children outside the U.S.
- Fundraising data and donor trust
- Tied to the dependence on ALSAC: donor analytics and privacy-safe AI tools, in line with ALSAC's use of aggregated data for donor communications.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like St. Jude Children's Research Hospital?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- St. Jude Children's Research Hospital, Inc. and Subsidiaries - Consolidated Financial Statements FY2025 (year ended June 30, 2025) and single audit
- St. Jude Children's Research Hospital, Inc. (Memphis, Tennessee) is a not-for-profit research, treatment and education center for children with catastrophic illnesses; "No family ever pays the Hospital for the care their child receives". It sees more than 9,300 patients a year, about 75,000 hospital visits a year, mostly outpatient within research programs.
- FY2025 (year ended June 30, 2025) total expenses were $1,897,572K (FY2024: $1,772,679K): Research $883,216K, Patient care services $726,650K, Education, training and community services $146,234K, administrative and general $141,472K.
- Own revenues cover a small part of the cost: total revenues, gains and other support of $341,483K (net patient service revenue $141,306K, research grants and contracts $162,425K, other $37,752K). The gap is funded by its fundraising affiliate ALSAC: net support received from ALSAC was $1,878,045K (FY2024: $1,677,081K).
- ALSAC, sole beneficiary relationship: ALSAC total revenues, gains and other support of $3,735,743K and net assets of $10,765,019K at June 30, 2025; investments of $10,032,383K. ALSAC "has approximately $7.3 billion available to support hospital operations over the next twelve months".
- Total net assets of the Hospital reached $12,561,643K (FY2024: $11,323,206K), most of it the interest in ALSAC's net assets.
- Heavy building programme: capital expenditures of $452,643K (FY2024: $380,188K); construction in progress of $774,406K, including $639.5 million for clinical outpatient facilities with a total estimated cost of $1 billion, expected substantially complete in calendar 2026.
- Biggest cost lines: salaries and benefits $1,041,996K; professional fees and contract services $393,301K; supplies $214,936K; depreciation $126,016K.
- Federal research funding is a visible risk area: total federal awards expended were $137,833,439 (almost all Department of Health and Human Services, $135,935,131); federal F&A cost recovery rates were 79.5%, 82% or 85%. Unmodified audit opinion, no findings, low-risk auditee.
- Management responsible for the statements: James Downing (President and CEO) and Pat Keel (EVP Chief Administrative & Financial Officer); Board of Governors chaired by Judy A. Habib.
- The new head of America's top children's hospital sees 'the dawn of a new era' for kid cancer treatment (AP interview)
- Dr. Charles W. M. Roberts, director of St. Jude's Comprehensive Cancer Center and an executive vice president, was named St. Jude president and CEO, succeeding Dr. James R. Downing after 12 years; he starts on Jan. 1, and Downing moves to a faculty role in Global Pediatric Medicine.
- Roberts: "I think we are at the dawn of a new era"; he sees "a once-in-a-lifetime opportunity" in the next several years.
- Thesis: a convergence of technological advances is producing treatments that kill childhood cancers more effectively with less impact on the patient, and is opening catastrophic childhood diseases beyond cancer.
- He will keep doing research as CEO to stay "at the cutting edge" and steer priorities.
- Constraints named: less pharma investment in childhood cancers and federal cuts to scientific research funding.
- Commitments: treatment stays free for families; services will expand to treat more children around the world, funded by ALSAC (ALSAC raised an average of $2.3 billion a year in 2021-2023 per The Chronicle of Philanthropy).
- Roberts on pharma: "We can't go all the way and completely replace what pharma does".
- Shifting the paradigm for pediatric cancer (STAT conversation with Charles W.M. Roberts)
- STAT Brand Studio (sponsored) on-stage conversation, May 18, 2026: Dr. Charles W.M. Roberts, St. Jude EVP and director of the Comprehensive Cancer Center, interviewed by Matthew Herper.
- Childhood cancer survival rose from about 10 to 20% when St. Jude opened in 1962 to close to 85% in 2026, yet cancer is still the number one cause of death by disease for US children, and toxic therapies leave lifelong consequences.
- Past gains came from non-specific toxins; "now in 2026, I think we really have a once-in-a-lifetime opportunity to change all of this."
- He compares the moment to the iPhone: a convergence of technologies - knowledge of true cancer vulnerabilities plus new therapeutic modalities (AI-designed small molecules, PROTACs and glues, RNA therapeutics, antibody drug conjugates, CAR-T cells).
- Pediatric cancers are often driven by lost tumor suppressors; the cancer dependency map is used to find vulnerabilities.
- These modalities could also make inherited genetic diseases of children treatable.
- Hope for next year: third-generation CAR-T working in DIPG, and therapies that are "truly are curative instead of long-term toxicity".
- St. Jude Children's Research Hospital's fundraiser selects new CEO in midst of global expansion (AP interview with Ike Anand)
- ALSAC, St. Jude's fundraising and awareness organization, promoted Ike Anand (COO since 2020, 15 years at Expedia Group before) to president and CEO on July 8, 2025.
- ALSAC raised more than $2.5 billion for the hospital in 2024 according to tax filings, and is navigating a global expansion and a more complicated US funding landscape.
- ALSAC board chair Dr. Frederick M. Azar credits Anand with redefining strategic direction, including the six-year $12.9 billion plan to provide pediatric cancer cures and treatments globally.
- Anand: "My role is to make sure that ALSAC is able to deliver on its promises to St. Jude so that St. Jude can continue to dream big"
- Culture of "testing and learning"; data, donor relationships and global teams carried over from Expedia.
- AI guides donor communications, using aggregated data, not donors' individual data; donor trust and privacy are "really, really vital".
- US health policy changes do not change the focus: the mission covers all 400,000 children diagnosed with cancer worldwide.
Questions about St. Jude Children's Research Hospital
What does St. Jude Children's Research Hospital do?
St. Jude is a not-for-profit research, treatment and education center in Memphis that seeks causes and cures for catastrophic childhood illnesses and treats more than 9,300 patients a year free of charge to families.
How is St. Jude funded?
Its own revenues of $341,483K in FY2025 covered a minority of its $1,897,572K of expenses; ALSAC, its fundraising affiliate, provided net support of $1,878,045K.
Who leads St. Jude Children's Research Hospital?
Dr. James R. Downing led St. Jude for 12 years; Dr. Charles W. M. Roberts, director of the Comprehensive Cancer Center, was named president and CEO starting Jan. 1. Judy A. Habib chairs the Board of Governors.
What is St. Jude's strategy?
Use a convergence of new therapeutic technologies to cure more childhood cancers with less toxicity, extend to other catastrophic childhood diseases, and expand care to more children around the world.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)